| Original language | English |
|---|---|
| Pages (from-to) | e145-e146 |
| Journal | Diabetes care |
| Volume | 41 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - 2018 Nov 1 |
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Advanced and Specialised Nursing
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy : Report of a randomized study. Diabetes care 2018;41:1275–1284. / Itoh, Hiroshi; Ueshima, Kenji; Komuro, Issei.
In: Diabetes care, Vol. 41, No. 11, 01.11.2018, p. e145-e146.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy
T2 - Report of a randomized study. Diabetes care 2018;41:1275–1284
AU - Itoh, Hiroshi
AU - Ueshima, Kenji
AU - Komuro, Issei
N1 - Funding Information: Acknowledgments. EDIT, Inc. (Tokyo, Japan) provided medical writing and editing. Funding and Duality of Interest. The EMPATHY study was supported by Shionogi & Co., Ltd. H.I. reports grants and personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Daiichi Sankyo Company, Limited, MSD K.K., Mitsubishi Tanabe Pharma Corporation, Shionogi & Co., Ltd., and Taisho Toyama Pharmaceutical Co., Ltd.; grants from Sumitomo Dainippon Pharma Co., Ltd., Astellas Pharma Inc., Kyowa Hakko Kirin Co., Ltd., Teijin Pharma Limited, Mo-chida Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and Eli Lilly Japan K.K.; and personal fees from Nipro Corporation and SBI Pharmaceuticals Co., Ltd. outside the submitted work. K.U. reports other (contracted work) from Shionogi & Co., Ltd. during the conduct of the study and personal fees from Shionogi & Co., Ltd. outside the submitted work. I.K. reports personal fees from Shionogi & Co., Ltd. during the conduct of the study and grants and Funding Information: personal fees from Takeda Pharmaceutical Company Limited, Nippon Boehringer Ingelheim Co., Ltd., Astellas Pharma Inc., Daiichi Sankyo Company, Limited, and Otsuka Pharmaceutical Co., Ltd. and grants from MSD K.K., Shionogi & Co., Ltd., GlaxoSmithKline K.K., Sanofi K.K., Genzyme Japan K.K., SumitomoDainipponPharmaCo., Ltd., Mitsubishi Tanabe Pharma Corporation, and Bristol-Myers Squibb outside the submitted work. No other potential conflicts of interest relevant to this article were reported.
PY - 2018/11/1
Y1 - 2018/11/1
UR - http://www.scopus.com/inward/record.url?scp=85055147649&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055147649&partnerID=8YFLogxK
U2 - 10.2337/dci18-0028
DO - 10.2337/dci18-0028
M3 - Letter
C2 - 30348847
AN - SCOPUS:85055147649
VL - 41
SP - e145-e146
JO - Diabetes Care
JF - Diabetes Care
SN - 1935-5548
IS - 11
ER -